Management of an increasing prostate-specific antigen level after negative prostate biopsy.
- Author(s): Shinohara, Katsuto;
- Nguyen, Hao;
- Masic, Selma
- et al.
Published Web Locationhttp://www.sciencedirect.com/science/article/pii/S0094014314000111
Patients who have a previously negative biopsy in the setting of clinical suspicion of prostate cancer still have a high risk of harboring significant undiagnosed disease. Various markers such as prostate-specific antigen (PSA) velocity, PSA density, PCA3, and newer markers may aid in repeat biopsy selection. Repeating the same biopsy procedure in such patients does not yield high cancer detection rates. More anteriorly directed transrectal or transperineal biopsies are indicated. Multiparametric magnetic resonance imaging can detect abnormal areas, and lesion-targeted biopsies can improve the cancer detection rate.